CFDE Data Portal | Search IGFBP-AS1

	Label	Description
	IGFBP-AS1 Gene (Entity type)	ENSG00000223874 - IGFBP5 antisense RNA 1
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE114883 romidepsin T cell 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE102505 5 V 0 TUNICAMYCIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE150244 TRIM8 knockout 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 progesterone fibroblast 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 2 V 4 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

IGFBP-AS1

ENSG00000223874 - IGFBP5 antisense RNA 1

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn

A Gene Set from LINCS

GSE114883 romidepsin T cell 1 v 2 human up

A Gene Set from LINCS

GSE239844 crizotinib 6 v 9 human up

A Gene Set from LINCS

GSE102505 5 V 0 TUNICAMYCIN HUMAN DN

A Gene Set from LINCS

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE150244 TRIM8 knockout 3 v 0 human dn

A Gene Set from LINCS

GSE220806 progesterone fibroblast 1 v 3 human dn

A Gene Set from LINCS

GSE135350 2 V 4 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE138789 metformin 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.